NCT00352560View on ClinicalTrials.gov

Electrophysiological Effects of Irbesartan in Patients With Paroxysmal Atrial Fibrillation (AF)

PHASE3CompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

July 31, 2006

Primary Completion Date

June 30, 2007

Study Completion Date

June 30, 2007

Conditions
Atrial Fibrillation
Interventions
DRUG

Irbesartan

Tablets, Oral, 300 mg, once daily, 30 days.

DRUG

Placebo

Tablets, Oral, 0 mg, once daily, 30 days.

Trial Locations (3)

28040

Local Institution, Madrid

28046

Local Institution, Madrid

28905

Local Institution, Madrid

Sponsors

Collaborators (1)

Sanofi
All Listed Sponsors
collaborator

Sanofi

INDUSTRY

lead

Bristol-Myers Squibb

INDUSTRY